Company Overview
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.
Recent News
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
Stock Overview
Symbol
SCYX
Exchange
Nasdaq
Market Cap
57.92m
Last Price
$1.53
52-Week Range
$1.26 - $3.07
10/11/2024 08:00 PM EDT